Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results


1.		Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Active				18 and over				Other				2006-00055-18 NCT00415103

Last Modified: 5/29/2008 First Published: 5/11/2007


2.		Phase III Randomized Study of Different Combinations of Granisetron Hydrochloride, Dexamethasone, Prochlorperazine, Aprepitant, and Palonosetron Hydrochloride in Preventing Delayed Nausea in Women Undergoing Chemotherapy for Chemotherapy-Naive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				18 and over				NCI				URCC-04-02 URCC 0402, URCC-U1105, U1105, NCT00475085

Last Modified: 5/27/2008 First Published: 10/30/2007


3.		Phase III Randomized Study of Palonosetron Hydrochloride and Dexamethasone With or Without Dronabinol in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy for Solid tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				18 and over				NCI				MDA-2006-0841 2006-0841, NCT00553059


4.		Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care, Treatment				Active				18 to 65				Other				2005-0506 NCT00412425

Last Modified: 8/21/2008 First Published: 9/23/2006


5.		Phase II Study of Aprepitant, Palonosetron Hydrochloride, and Dexamethasone in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving FOLFOX or FOLFIRI Chemotherapy for Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Active				18 and over				NCI				OHSU-SOL-06006-LM OHSU-IRB-2302, NCT00381862

Last Modified: 6/9/2008 First Published: 3/6/2008


6.		Phase II Pilot Study of Palonosetron Hydrochloride, Aprepitant, and Low-Dose Dexamethasone in Preventing Nausea and Vomiting in Patients Undergoing High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma or Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Active				18 to 75				Other				KUMC-10862 10862, MGI-KUMC-10862, NCT00631930


7.		Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Approved-not yet active				18 and over				Other				00002273 NCT00636805

Last Modified: 4/29/2008 First Published: 6/16/2006


8.		Study of Dexamethasone in Combination With Either Ondansetron or Palonosetron Hydrochloride in Preventing Acute and Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Early-Stage Breast Cancer Undergoing Chemotherapy Comprising Doxorubicin Hydrochloride and Cyclophosphamide

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Supportive care, Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				UWCC-UW-6140 UWCC-05-9579-H/D, FHCRC-6140, MGI-FHCRC-6140, NCT00343863


9.		Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Supportive care, Treatment				Active				18 to 65				Other				2005-0664 NCT00410488

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute